NCT03812549 2025-03-04
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
Sichuan University
Phase 1 Completed
Clinical Trials
11 trialsNCT05979818 2024-11-19
BRIO
Second Xiangya Hospital of Central South University
Phase 1 Recruiting
NCT04220944 2024-08-01
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
Shanghai Zhongshan Hospital
Phase 1 Active not recruiting
NCT06431685 2024-05-28
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
Sichuan University
Phase 1 Recruiting
NCT04906044 2023-11-18
STARS-RC03
The First Hospital of Jilin University
Phase 1 Active not recruiting
NCT03732664 2023-03-24
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Completed
NCT05225116 2023-02-08
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown
NCT05363722 2022-05-06
A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT05008861 2021-08-17
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT03987867 2020-07-07
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT04104074 2020-07-07
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown